Microbot Medical Granted Patent Allowance in Japan; Global Jurisdictions Recognizing Novel ‘One & Done’ Technology
February 04 2021 - 7:00AM
Microbot Medical Inc. (Nasdaq: MBOT) has received official
notification from the Japan Patent Office (JPO) that it intends to
grant the Company a patent for its ‘One & Done’ guidewire
technology for use with endoluminal interventions. Japan is the
second jurisdiction to grant a patent for the ‘One & Done’
guidewire technology and further protects the novel technology the
Company is currently developing.
“We are advancing our LIBERTY™ Robotic system,
specifically the ‘One &Done’ technology, and we are committed
to establish and secure barriers of entry through protecting our
intellectual property and know-how,” commented Harel Gadot, CEO,
President and Chairman. “We have received positive physician and
industry feedback since unveiling the LIBERTY Robotic system last
year, and we will integrate their shared opinion as we expand our
IP platform.”
The allowed claims cover a double guidewire
(movable core guidewire) comprising a first hollow guidewire (outer
tube) and a second guidewire (inner core) deployed within the first
guidewire (outer tube), and an adjuster mechanism operable to
displace the second guidewire (inner core) longitudinally relative
to the first guidewire between at least three states. Each such
state is characterized with its distal tip curvature and
stiffness.
Globally, the Company now holds a total of 41
patents issued/allowed and 22 pending patent applications.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
pre-clinical medical device company that specializes in
transformational micro-robotic technologies, focused primarily on
both natural and artificial lumens within the human body.
Microbot’s current proprietary technological platforms provide the
foundation for the development of a Multi Generation Pipeline
Portfolio (MGPP).
Microbot Medical was founded in 2010 by Harel
Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of
improving clinical outcomes for patients and increasing
accessibility through the use of micro-robotic technologies.
Further information about Microbot Medical is available at
http://www.microbotmedical.com.
Safe Harbor
Statements pertaining to the registered direct
offering, timing, the amount and anticipated use of proceeds and
statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for Microbot Medical Inc. and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions and
the satisfaction of customary closing conditions, risks inherent in
the development and/or commercialization of potential products,
including LIBERTY and SCS, the outcome of its studies to evaluate
LIBERTY, SCS and other existing and future technologies,
uncertainty in the results of pre-clinical and clinical trials or
regulatory pathways and regulatory approvals, uncertainty resulting
from the COVID-19 pandemic, need and ability to obtain future
capital, and maintenance of intellectual property rights.
Additional information on risks facing Microbot Medical can be
found under the heading “Risk Factors” in Microbot Medical’s
periodic reports filed with the Securities and Exchange Commission
(SEC), which are available on the SEC’s web site at www.sec.gov.
Microbot Medical disclaims any intent or obligation to update these
forward-looking statements, except as required by law.
Investor Contact:
Michael PolyviouEVC
Groupmpolyviou@evcgroup.com732-933-2754
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Apr 2023 to Apr 2024